Maryland House Bill HB1461

Maryland 2026 Regular Session

• Introduced: 2/13/26
• Refer: 2/13/26

Caption

Health Insurance - Coverage for Specialty Drugs - Rheumatologic Conditions

Impact

If enacted, HB 1461 will significantly enhance access to treatment for patients with rheumatologic disorders by ensuring that health insurance plans cannot deny coverage for medically appropriate specialty drugs administered by qualified healthcare providers. This change is critical as it reinforces the role of clinical providers in managing patient care, ensuring they receive timely and adequate compensation for their services. The bill supports a more integrated healthcare model, emphasizing direct patient-provider relationships and minimizing outsourcing to specialty pharmacies.

Summary

House Bill 1461 aims to expand coverage for specialty drugs used in the treatment of rheumatologic conditions by prohibiting certain health insurers from excluding these drugs when dispensed by qualified in-network providers. The bill addresses the increasing reliance on specialty medications for complex autoimmune diseases and seeks to enhance the reimbursement rates for providers who administer these treatments in their offices rather than through designated specialty pharmacies. This approach aims to eliminate delays and errors caused by pharmacy steering policies that can disrupt patient care.

Contention

One notable point of contention surrounding HB 1461 arises from concerns over the financial implications for insurance companies and pharmacy benefit managers. Some stakeholders argue that the bill could lead to increased costs for insurers, which might be passed on to consumers through higher premiums. Additionally, there are debates over how this law would interact with existing regulations governing specialty drugs and whether it could inadvertently limit options for patients who might benefit from using specialty pharmacies that have different logistic capabilities.